Browse P2RY11

Summary
SymbolP2RY11
Namepurinergic receptor P2Y, G-protein coupled, 11
Aliases P2Y11; purinergic receptor P2Y11; P2Y purinoceptor 11
Chromosomal Location19p13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane; Multi-pass membrane protein.
Domain PF00001 7 transmembrane receptor (rhodopsin family)
Function

Receptor for ATP and ADP coupled to G-proteins that activate both phosphatidylinositol-calcium and adenylyl cyclase second messenger systems. Not activated by UTP or UDP.

> Gene Ontology
 
Biological Process GO:0001973 adenosine receptor signaling pathway
GO:0006140 regulation of nucleotide metabolic process
GO:0006164 purine nucleotide biosynthetic process
GO:0006171 cAMP biosynthetic process
GO:0007190 activation of adenylate cyclase activity
GO:0007200 phospholipase C-activating G-protein coupled receptor signaling pathway
GO:0009150 purine ribonucleotide metabolic process
GO:0009152 purine ribonucleotide biosynthetic process
GO:0009165 nucleotide biosynthetic process
GO:0009187 cyclic nucleotide metabolic process
GO:0009190 cyclic nucleotide biosynthetic process
GO:0009260 ribonucleotide biosynthetic process
GO:0014074 response to purine-containing compound
GO:0019722 calcium-mediated signaling
GO:0019932 second-messenger-mediated signaling
GO:0023041 neuronal signal transduction
GO:0030799 regulation of cyclic nucleotide metabolic process
GO:0030801 positive regulation of cyclic nucleotide metabolic process
GO:0030802 regulation of cyclic nucleotide biosynthetic process
GO:0030804 positive regulation of cyclic nucleotide biosynthetic process
GO:0030808 regulation of nucleotide biosynthetic process
GO:0030810 positive regulation of nucleotide biosynthetic process
GO:0030814 regulation of cAMP metabolic process
GO:0030816 positive regulation of cAMP metabolic process
GO:0030817 regulation of cAMP biosynthetic process
GO:0030819 positive regulation of cAMP biosynthetic process
GO:0031279 regulation of cyclase activity
GO:0031281 positive regulation of cyclase activity
GO:0033198 response to ATP
GO:0035587 purinergic receptor signaling pathway
GO:0035588 G-protein coupled purinergic receptor signaling pathway
GO:0035589 G-protein coupled purinergic nucleotide receptor signaling pathway
GO:0035590 purinergic nucleotide receptor signaling pathway
GO:0045761 regulation of adenylate cyclase activity
GO:0045762 positive regulation of adenylate cyclase activity
GO:0045981 positive regulation of nucleotide metabolic process
GO:0046058 cAMP metabolic process
GO:0046390 ribose phosphate biosynthetic process
GO:0046683 response to organophosphorus
GO:0051339 regulation of lyase activity
GO:0051349 positive regulation of lyase activity
GO:0052652 cyclic purine nucleotide metabolic process
GO:0071318 cellular response to ATP
GO:0071407 cellular response to organic cyclic compound
GO:0071417 cellular response to organonitrogen compound
GO:0072522 purine-containing compound biosynthetic process
GO:1900371 regulation of purine nucleotide biosynthetic process
GO:1900373 positive regulation of purine nucleotide biosynthetic process
GO:1900542 regulation of purine nucleotide metabolic process
GO:1900544 positive regulation of purine nucleotide metabolic process
GO:1901293 nucleoside phosphate biosynthetic process
Molecular Function GO:0001608 G-protein coupled nucleotide receptor activity
GO:0001609 G-protein coupled adenosine receptor activity
GO:0001614 purinergic nucleotide receptor activity
GO:0016502 nucleotide receptor activity
GO:0030594 neurotransmitter receptor activity
GO:0035586 purinergic receptor activity
GO:0045028 G-protein coupled purinergic nucleotide receptor activity
GO:0045031 ATP-activated adenosine receptor activity
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG hsa04080 Neuroactive ligand-receptor interaction
Reactome R-HSA-373076: Class A/1 (Rhodopsin-like receptors)
R-HSA-416476: G alpha (q) signalling events
R-HSA-418555: G alpha (s) signalling events
R-HSA-388396: GPCR downstream signaling
R-HSA-500792: GPCR ligand binding
R-HSA-881907: Gastrin-CREB signalling pathway via PKC and MAPK
R-HSA-418038: Nucleotide-like (purinergic) receptors
R-HSA-417957: P2Y receptors
R-HSA-162582: Signal Transduction
R-HSA-372790: Signaling by GPCR
Summary
SymbolP2RY11
Namepurinergic receptor P2Y, G-protein coupled, 11
Aliases P2Y11; purinergic receptor P2Y11; P2Y purinoceptor 11
Chromosomal Location19p13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between P2RY11 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolP2RY11
Namepurinergic receptor P2Y, G-protein coupled, 11
Aliases P2Y11; purinergic receptor P2Y11; P2Y purinoceptor 11
Chromosomal Location19p13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of P2RY11 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA Resistant to T cell-mediated killing
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolP2RY11
Namepurinergic receptor P2Y, G-protein coupled, 11
Aliases P2Y11; purinergic receptor P2Y11; P2Y purinoceptor 11
Chromosomal Location19p13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of P2RY11 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.1110.81
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.6720.502
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.6840.391
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.5050.441
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.4090.801
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 471.6660.439
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.070.785
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.2820.534
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.1710.722
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.6680.492
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.7410.596
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 6823000.999
> Mutation difference between responders and non-responders
 

There is no record.
Summary
SymbolP2RY11
Namepurinergic receptor P2Y, G-protein coupled, 11
Aliases P2Y11; purinergic receptor P2Y11; P2Y purinoceptor 11
Chromosomal Location19p13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of P2RY11. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolP2RY11
Namepurinergic receptor P2Y, G-protein coupled, 11
Aliases P2Y11; purinergic receptor P2Y11; P2Y purinoceptor 11
Chromosomal Location19p13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of P2RY11. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by P2RY11.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolP2RY11
Namepurinergic receptor P2Y, G-protein coupled, 11
Aliases P2Y11; purinergic receptor P2Y11; P2Y purinoceptor 11
Chromosomal Location19p13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of P2RY11. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolP2RY11
Namepurinergic receptor P2Y, G-protein coupled, 11
Aliases P2Y11; purinergic receptor P2Y11; P2Y purinoceptor 11
Chromosomal Location19p13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of P2RY11 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolP2RY11
Namepurinergic receptor P2Y, G-protein coupled, 11
Aliases P2Y11; purinergic receptor P2Y11; P2Y purinoceptor 11
Chromosomal Location19p13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between P2RY11 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolP2RY11
Namepurinergic receptor P2Y, G-protein coupled, 11
Aliases P2Y11; purinergic receptor P2Y11; P2Y purinoceptor 11
Chromosomal Location19p13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting P2RY11 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting P2RY11.
ID Name Drug Type Targets #Targets
DB00171ATPSmall MoleculeABCA1, ABCB1, ABCB11, ABCC1, ABCC2, ABCC4, ABCC6, ABCC8, ABCC9, AB ......42